Vir Biotechnology (VIR) EBITDA (2018 - 2026)

Vir Biotechnology has disclosed EBITDA across 9 years of filings, most recently posting -$132.3 million for Q1 2026.

• EBITDA for Q1 2026 came in at -$132.3 million, up 5.2% year-over-year; the trailing twelve-month figure through Mar 2026 was -$472.1 million (up 27.0% YoY), and the FY2025 annual result was -$479.3 million, up 18.37% from the prior year.
• EBITDA came in at -$132.3 million for Q1 2026 at Vir Biotechnology, down from -$47.9 million in the prior quarter.
• In the past five years, EBITDA ranged from a high of $1.0 billion in Q1 2022 to a low of -$231.3 million in Q3 2024.
• The 5-year median for EBITDA is -$139.5 million (2025), against an average of -$61.8 million.
• Peak annual rise in EBITDA reached 739.1% in 2022, while the deepest fall reached 469.11% in 2022.
• Vir Biotechnology's EBITDA stood at -$150.5 million in 2022, then rose by 7.63% to -$139.0 million in 2023, then grew by 15.73% to -$117.2 million in 2024, then soared by 59.09% to -$47.9 million in 2025, then sank by 176.06% to -$132.3 million in 2026.
• The last three EBITDA figures came in at -$132.3 million (Q1 2026), -$47.9 million (Q4 2025), and -$173.4 million (Q3 2025), per Business Quant data.